It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There are no assays for detecting B. burgdorferi antigen in blood of infected Lyme disease individuals. Here, we provide proof-of-principle evidence that we can quantify B. burgdorferi antigen in spiked blood using a portable smartphone-based fluorescence microscope that measures immunoagglutination on a paper microfluidic chip. We targeted B. burgdorferi OspA to develop a working prototype and added examples of two antigens (OspC and VlsE) that have diagnostic value for discrimination of Lyme disease stage. Using an extensively validated monoclonal antibody to OspA (LA-2), detection of OspA antigen had a broad linear range up to 100 pg/mL in 1% blood and the limit of detection (LOD) was 100 fg/mL (= 10 pg/mL in undiluted blood), which was 1000 times lower than our target of 10 ng/mL. Analysis of the two other targets was done using polyclonal and monoclonal antibodies. OspC antigen was detected at LOD 100 pg/mL (= 10 ng/mL of undiluted blood) and VlsE antigen was detected at LOD 1–10 pg/mL (= 0.1–1 ng/mL of undiluted blood). The method is accurate and was performed in 20 min from sample to answer. When optimized for detecting several B. burgdorferi antigens, this assay may differentiate active from past infections and facilitate diagnosis of Lyme disease in the initial weeks of infection, when antibody presence is typically below the threshold to be detected by serologic methods.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The University of Arizona, Department of Biomedical Engineering, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
2 University of Tennessee Health Science Center, Department of Microbiology, Immunology and Biochemistry, Memphis, USA (GRID:grid.267301.1) (ISNI:0000 0004 0386 9246); Merck & Co., West Point, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793); Immuno Technologies, Inc, Memphis, USA (GRID:grid.504620.5)
3 The University of Arizona, College of Medicine, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
4 University of Tennessee Health Science Center, Department of Microbiology, Immunology and Biochemistry, Memphis, USA (GRID:grid.267301.1) (ISNI:0000 0004 0386 9246); Immuno Technologies, Inc, Memphis, USA (GRID:grid.504620.5); US Biologic, Inc, Memphis, USA (GRID:grid.487088.b)
5 University of Tennessee Health Science Center, Department of Microbiology, Immunology and Biochemistry, Memphis, USA (GRID:grid.267301.1) (ISNI:0000 0004 0386 9246); Immuno Technologies, Inc, Memphis, USA (GRID:grid.504620.5)